We are live on ! Find out more
SI

Sofinnova Investments Portfolio holdings

AUM $1.93B
1-Year Est. Return 134.74%
This Fund
S&P 500
This Quarter Est. Return
+18.15%
1 Year Est. Return
+134.74%
3 Year Est. Return
+450.5%
5 Year Est. Return
+913.18%
10 Year Est. Return
–
AUM
$1.53B
AUM Growth
-$36.8M
Cap. Flow
-$96.9M
Cap. Flow %
-6.35%
Top 10 Hldgs %
64.78%
Holding
69
New
17
Increased
8
Reduced
13
Closed
17

Top Buys

Rank Stock Value
1
AZN icon
AstraZeneca
AZN
+$125M
2
VRTX icon
Vertex Pharmaceuticals
VRTX
+$49M
3
IDXX icon
Idexx Laboratories
IDXX
+$33.9M
4
EXEL icon
Exelixis
EXEL
+$33.3M
5
BSX icon
Boston Scientific
BSX
+$31.8M

Top Sells

Rank Stock Value
1
KRTX
Karuna Therapeutics, Inc. Common Stock
KRTX
+$84M
2
LLY icon
Eli Lilly
LLY
+$47.1M
3
HZNP
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
+$44.6M
4
BIIB icon
Biogen
BIIB
+$36.9M
5
MRK icon
Merck
MRK
+$35.7M

Sector Composition

Rank Sector Weight
1 Healthcare 99.09%
2 Miscellaneous 0.91%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
SPRB
51
Spruce Biosciences
SPRB
$160M
$125K 0.01%
+774
New +$129K
ALNY icon
52
Alnylam Pharmaceuticals
ALNY
$34.5B
– –
-448
Closed -$89.7K
BIIB icon
53
Biogen
BIIB
$31.1B
– –
-132,600
Closed -$36.9M
BLUE
54
DELISTED
bluebird bio
BLUE
– –
-33,641
Closed -$2.14M
BMRN icon
55
BioMarin Pharmaceuticals
BMRN
$12.5B
– –
-359,035
Closed -$34.9M
KROS icon
56
Keros Therapeutics
KROS
$224M
– –
-77,100
Closed -$3.29M
KURA icon
57
Kura Oncology
KURA
$1.08B
– –
-616,169
Closed -$7.54M
LLY icon
58
Eli Lilly
LLY
$1T
– –
-137,100
Closed -$47.1M
NVCR icon
59
CALL
NovoCure
NVCR
$1.82B
– –
-50,000
Closed -$3.01M
SPY icon
60
PUT
State Street SPDR S&P 500 ETF Trust
SPY
$806B
– –
-200,000
Closed -$81.9M
SRPT icon
61
Sarepta Therapeutics
SRPT
$2.33B
– –
-119,065
Closed -$16.4M
TVTX icon
62
Travere Therapeutics
TVTX
$6.24B
– –
-1,263,721
Closed -$28.4M
IMGN
63
CALL
DELISTED
Immunogen Inc
IMGN
– –
-1,000,000
Closed -$3.84M
KDNY
64
DELISTED
Chinook Therapeutics, Inc. Common Stock
KDNY
– –
-1,002,348
Closed -$23.2M
ISEE
65
DELISTED
IVERIC bio, Inc. Common Stock
ISEE
– –
-905,982
Closed -$22M
RXDX
66
DELISTED
Prometheus Biosciences, Inc. Common Stock
RXDX
– –
-123,842
Closed -$13.3M
HZNP
67
DELISTED
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
– –
-408,819
Closed -$44.6M
CTIC
68
DELISTED
CTI BioPharma Corp. (DE) Common Stock
CTIC
– –
-2,794,542
Closed -$11.7M
1 2
3

Similar funds

GIA
Guyasuta Investment Advisors Pittsburgh, Pennsylvania $1.94B AUM 32.92% 1-Year Est. Return
EK
Evensky & Katz Coral Gables, Florida $1.94B AUM 22.01% 1-Year Est. Return
CTI
Community Trust & Investment Versailles, Kentucky $1.94B AUM 29.99% 1-Year Est. Return
SI
Standard Investments New York $1.93B AUM 6.23% 1-Year Est. Return
P3I
Progeny 3 Inc Kirkland, Washington $1.94B AUM 19.13% 1-Year Est. Return
TCM
Tao Capital Management San Francisco, California $1.94B AUM 48.68% 1-Year Est. Return
MCWS
McKinley Carter Wealth Services Wheeling, West Virginia $1.94B AUM 20.7% 1-Year Est. Return
SWM
Segment Wealth Management Houston, Texas $1.93B AUM 29.24% 1-Year Est. Return

Sofinnova Investments's Q2 2023 Portfolio in Review

As of Q2 2023, Sofinnova Investments held 69 positions worth $1.53B, down 2.4% from $1.56B the previous quarter. Its ten largest holdings account for 65% of the portfolio.

Sofinnova Investments withdrew a net $96.9M in Q2 2023, closing 17 positions and reducing 13 holdings. Its most notable exit was Eli Lilly, an estimated $47.1M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 99% of assets, up from 94% a quarter earlier, followed by Miscellaneous.

Against the trend, Sofinnova Investments opened a new position in AstraZeneca worth $121M.

  • Sofinnova Investments's largest Q2 2023 buy was AstraZeneca: 848,759 shares worth $121M.
  • Sofinnova Investments added most to Exelixis in Q2 2023, an estimated $33.3M increase.
  • Sofinnova Investments's biggest Q2 2023 reduction was Karuna Therapeutics, Inc. Common Stock, cutting an estimated $84M.
  • Sofinnova Investments fully exited Eli Lilly in Q2 2023, selling an estimated $47.1M.
  • Sofinnova Investments's ten largest holdings make up 65% of its $1.53B portfolio in Q2 2023.
  • Sofinnova Investments opened 17 new positions and closed 17 in Q2 2023.
  • Sofinnova Investments's portfolio value fell 2.4% quarter-over-quarter to $1.53B.

Based on Sofinnova Investments's 13F filing for Q2 2023, filed 14 Aug 2023.